It's been a banner year so far for Genfit S.A. (GNFT), a late-stage biopharmaceutical company developing drugs for rare and life-threatening liver diseases, whose stock price touched a two-year high of $6.13 yesterday.
The company has 5 assets that focus on Acute-on-chronic liver failure and its complications, of which two are in the clinical stage and three are in preclinical development.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com